Tracking Oral Antipsychotic Adherence

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.007

4 - Tracking Oral Antipsychotic Adherence

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

That people with chronic illness do not take all of their oral medications is well established, and schizophrenia is not unique in this regard. A World Health Organization study estimated that medication adherence among patients with chronic diseases averages only 50% in developed countries, with recent data indicating a rate of 45% for hypertension specifically [1, 2]. Unlike hypertension, where the impact of nonadherence might not be felt for years, poor adherence with oral antipsychotic therapy can result in psychotic relapse within days or weeks, leading to hospitalization, social disruption, and legal sequelae (e.g. increased risk for violence) [3, 4].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 87 - 113

DOI: https://doi.org/10.1017/9781009002103.007 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Lam, W. Y. and Fresco, P. (2015). Medication adherence measures: An overview. Biomed Res Int, 2015, 217047.Google Scholar

Abegaz, T. M., Shehab, A., Gebreyohannes, E. A., et al. (2017). Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore), 96, e5641.Google Scholar

Buchanan, A., Sint, K., Swanson, J., et al. (2019). Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry, 176, 694–701.Google Scholar

Velligan, D. I., Maples, N. J., Pokorny, J. J., et al. (2020). Assessment of adherence to oral antipsychotic medications: What has changed over the past decade? Schizophr Res, 215, 17–24.Google Scholar

Takeuchi, H., Siu, C., Remington, G., et al. (2019). Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology, 44, 1036–1042.Google Scholar

Kishi, T., Oya, K., and Iwata, N. (2016). Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res, 246, 750–755.Google Scholar

Kishimoto, T., Hagi, K., Nitta, M., et al. (2018). Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: A meta-analysis of prospective and retrospective cohort studies. Schizophr Bull, 44, 603–619.Google Scholar

Miura, G., Misawa, F., Kawade, Y., et al. (2019). Long-acting injectables versus oral antipsychotics: A retrospective bidirectional mirror-image study. J Clin Psychopharmacol, 39, 441–445.Google Scholar

Weiden, P. J., Schooler, N. R., Weedon, J. C., et al. (2009). A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. J Clin Psychiatry, 70, 1397–1406.Google Scholar

Weiden, P. J., Schooler, N. R., Weedon, J. C., et al. (2012). Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study. J Clin Psychiatry, 73, 1224–1233.Google Scholar

Subotnik, K. L., Casaus, L. R., Ventura, J., et al. (2015). Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: A randomized clinical trial. JAMA Psychiatry, 72, 822–829.Google Scholar

Kane, J. M., Schooler, N. R., Marcy, P., et al. (2019). Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): Results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry, 80, 18m12546.Google Scholar

Abdel-Baki, A., Medrano, S., Maranda, C., et al. (2020). Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol, 35, 221–228.Google Scholar

Kane, J. M., Schooler, N. R., Marcy, P., et al. (2020). Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: A randomized clinical trial. JAMA Psychiatry, 77, 1–8.Google Scholar

Medrano, S., Abdel-Baki, A., Stip, E., et al. (2018). Three-year naturalistic study on early use of long-acting injectable antipsychotics in first episode psychosis. Psychopharmacol Bull, 48, 25–61.Google Scholar

Robinson, D. G., Subramaniam, A., Fearis, P. J., et al. (2019). Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv, appips201900236.Google Scholar

Lindenmayer, J. P., Glick, I. D., Talreja, H., et al. (2020). Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol, 40, 346–349.Google Scholar

Brain, C., Sameby, B., Allerby, K., et al. (2014). Twelve months of electronic monitoring (MEMS) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol, 24, 215–222.Google Scholar

Velligan, D. I., Wang, M., Diamond, P., et al. (2007). Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv, 58, 1187–1192.Google Scholar

Yaegashi, H., Kirino, S., Remington, G., et al. (2020). Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis. CNS Drugs, 34, 579–598.Google Scholar

Byerly, M. J., Thompson, A., Carmody, T., et al. (2007). Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv, 58, 844–847.Google Scholar

Remington, G., Teo, C., Mann, S., et al. (2013). Examining levels of antipsychotic adherence to better understand nonadherence. J Clin Psychopharmacol, 33, 261–263.Google Scholar

MacEwan, J. P., Forma, F. M., Shafrin, J., et al. (2016). Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm, 22, 1349–1361.Google Scholar

Lopez, V. L., Shaikh, A., Merson, J., et al. (2017). Accuracy of clinician assessments of medication status in the emergency setting – a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol, 37, 310–314.Google Scholar

Kurokawa, S., Kishimoto, T., Su, K.-P., et al. (2019). Psychiatrists’ perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophr Res, 211, 105–107.Google Scholar

Velligan, D. I., Lam, Y. W., Glahn, D. C., et al. (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophr Bull, 32, 724–742.Google Scholar

Nieuwlaat, R., Wilczynski, N., Navarro, T., et al. (2014). Interventions for enhancing medication adherence. Cochrane Database Syst Rev, 2014, CD000011.Google Scholar

Thompson, L., Howes, C., and McCabe, R. (2016). Effect of questions used by psychiatrists on therapeutic alliance and adherence. Br J Psychiatry, 209, 40–47.Google Scholar

McCabe, R., Healey, P. G., Priebe, S., et al. (2013). Shared understanding in psychiatrist–patient communication: Association with treatment adherence in schizophrenia. Patient Educ Couns, 93, 73–79.Google Scholar

Sapra, M., Weiden, P. J., Schooler, N. R., et al. (2014). Reasons for adherence and nonadherence: A pilot study comparing first- and multi-episode schizophrenia patients. Clin Schizophr Relat Psychoses, 7, 199–206.Google Scholar

Hogan, T. P., Awad, A. G., and Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med, 13, 177–183.Google Scholar

Byerly, M. J., Nakonezny, P. A., and Rush, A. J. (2008). The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res, 100, 60–69.Google Scholar

Xu, D. R., Gong, W., Gloyd, S., et al. (2018). Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China. Schizophr Res, 201, 307–314.Google Scholar

McEvoy, J. P., Byerly, M., Hamer, R. M., et al. (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA, 311, 1978–1987.Google Scholar

Nakonezny, P. A., Lindow, J. C., Stroup, T. S., et al. (2020). A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Schizophr Res, 220, 92–97.Google Scholar

Pfeiffer, P. N., Ganoczy, D., and Valenstein, M. (2008). Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv, 59, 1207–1210.Google Scholar

Beebe, L. H., Smith, K., and Phillips, C. (2017). Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. J Psychosoc Nurs Ment Health Serv, 55, 29–36.Google Scholar

Xu, D. R., Xiao, S., He, H., et al. (2019). Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial. PLoS Med, 16, e1002785.Google Scholar

Uslu, E. and Buldukoglu, K. (2020). Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. Perspect Psychiatr Care, 56, 63–71.Google Scholar

Gaebel, W., Riesbeck, M., von Wilmsdorff, M., et al. (2010). Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol, 20, 310–316.Google Scholar

Quirk, A., Chaplin, R., Hamilton, S., et al. (2013). Communication about adherence to long-term antipsychotic prescribing: An observational study of psychiatric practice. Soc Psychiatry Psychiatr Epidemiol, 48, 639–647.Google Scholar

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr, 19, 432–438.Google Scholar

Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 24, 70–78.Google Scholar

Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136–144.Google Scholar

Müller, J., Keiser, M., Drozdzik, M., et al. (2017). Expression, regulation and function of intestinal drug transporters: An update. Biol Chem, 398, 175–192.Google Scholar

Jönsson, A. K., Spigset, O., and Reis, M. (2019). A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit, 41, 348–356.Google Scholar

Lee, J., Bies, R., Takeuchi, H., et al. (2016). Quantifying intraindividual variations in plasma clozapine levels: A population pharmacokinetic approach. J Clin Psychiatry, 77, 681–687.Google Scholar

Ng, W., Uchida, H., Ismail, Z., et al. (2009). Clozapine exposure and the impact of smoking and gender: A population pharmacokinetic study. Ther Drug Monit, 31, 360–366.Google Scholar

Shvartsburd, A., Sajadi, C., Morton, V., et al. (1984). Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. J Clin Psychopharmacol, 4, 194–198.Google Scholar

Gitlin, M. J., Nuechterlein, K. H., Mintz, J., et al. (2000). Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression. Psychopharmacology, 148, 350–354.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

McCutcheon, R., Beck, K., Bloomfield, M. A., et al. (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol, 29, 892–897.Google Scholar

McCutcheon, R., Beck, K., D’Ambrosio, E., et al. (2018). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand, 137, 39–46.Google Scholar

Kylleso, L., Smith, R. L., Karlstad, O., et al. (2020). Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. NPJ Schizophr, 6, 17.Google Scholar

Roerig Division of Pfizer Inc. (2020). Geodon package insert. New York.Google Scholar

Beedham, C., Miceli, J. J., and Obach, R. S. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol, 23, 229–232.Google Scholar

Dalvie, D. and Di, L. (2019). Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacol Ther, 201, 137–180.Google Scholar

Zanger, U. M. and Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138, 103–141.Google Scholar

Zanger, U. M., Klein, K., Thomas, M., et al. (2014). Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. Clin Pharmacol Ther, 95, 258–261.Google Scholar

Manikandan, P. and Nagini, S. (2018). Cytochrome P450 structure, function and clinical significance: A review. Curr Drug Targets, 19, 38–54.Google Scholar

Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar